Core Insights - N2OFF, Inc. has announced that its subsidiary MitoCareX Bio has demonstrated preliminary in vitro data showing inhibition of pro-inflammatory responses in human immune cells using its proprietary MITOLINE discovery platform, which targets mitochondrial carriers for inflammatory metabolic diseases [1][2] Industry Overview - The market for inflammatory and inflammatory metabolic diseases is rapidly growing, with anti-inflammatory drugs projected to increase from approximately $122 billion in 2024 to nearly $275 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 8.4% [3] - Small-molecule immunomodulators are expected to expand from around $188 billion in 2025 to over $350 billion by 2035, indicating strong demand for targeted oral anti-inflammatory therapies [3] - Therapeutics for metabolic disorders, including key inflammatory metabolic diseases like diabetes, are estimated to be around $77 billion in 2024 and forecasted to exceed $120 billion by 2030 [3] Company Developments - MitoCareX Bio is utilizing the MITOLINE algorithm to create a focused library of small-molecule candidates, which are being evaluated through proprietary in vitro assays to assess mitochondrial function and inflammatory signaling [2][4] - The MITOLINE algorithm addresses a significant challenge in mitochondrial drug discovery by providing reliable 3D comparative models of mitochondrial carrier proteins, facilitating the identification of novel small-molecule scaffolds [4] - MitoCareX Bio plans to advance its most promising mitochondrial-targeted anti-inflammatory candidates toward pre-clinical studies while expanding its discovery efforts across additional mitochondrial carrier targets [5]